A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

This registry study is collecting blood and tissue samples (biospecimens) from patients with certain blood cancers — including acute myeloid leukemia (AML) and follicular lymphoma — to discover new biological markers that can improve diagnosis and treatment decisions over time. **You may be eligible if...** - You are willing to participate and provide biological samples - You have a confirmed diagnosis of AML (any secondary AML is allowed), OR - You have confirmed follicular lymphoma and meet specific subgroup criteria based on your disease status (newly diagnosed, high-risk, relapsed, or transformed) **You may NOT be eligible if...** - You are unwilling or unable to follow study procedures - For AML: you have already received standard treatment for AML - For follicular lymphoma: you do not meet the specific subgroup criteria (e.g., you have been previously treated when the study requires treatment-naïve) Talk to your doctor to see if this trial is right for you.